DelMar Pharmaceuticals Inc.

NASDAQ: DMPIHealthcare / Biotechnology / Canada
0.770000.00Vol 313 3731Y Perf -85.10%
Aug 20th, 2019 15:59
BID0.7500 ASK0.7700
Open0.7700 Previous Close0.7700
Pre-Market0.76 After-Trading0.77
 -0.01 -1.30%  - -%
Target Price
4.00 
Analyst Rating
Strong Buy 1.00
Potencial %
419.48 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)2 
Earnings Rating
Neutral
Price Range Ratio 52wk %
0.77 
Earnings Date
23rd Sep 2019

Today's Price Range

0.71000.7900

52wk Range

0.71008.50

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
-17.20%
1 Month
-39.84%
3 Months
-69.44%
6 Months
-76.81%
1 Year
-85.10%
3 Years
-98.82%
5 Years
-97.53%
10 Years
-

Name / TickerPriceChg.Chg.%
DMPI0.77000.00000.00
AAPL210.610.26000.12
GOOG1 182.69-15.7600-1.32
MSFT137.26-1.1500-0.83
XOM69.03-0.4200-0.60
WFC44.68-0.5700-1.26
JNJ130.60-1.6500-1.25
FB183.81-2.3600-1.27
GE8.38-0.2900-3.34
JPM107.31-1.3800-1.27
Earnings HistoryEstimateReportedSurprise %
Q01 2019--0.90-
Q04 2018-1.10-1.009.09
Q03 2018-1.00-1.30-30.00
Q02 2018-0.15-0.146.67
Q01 2018-0.17-0.18-5.88
Q04 2017-0.19-0.20-5.26
Q03 2017-0.18-0.180.00
Q02 2017-0.17-0.1323.53
Earnings Per EndEstimateRevision %Trend
12/2018 QR-0.070.00-
6/2019 QR-0.30--
6/2019 FY-0.70--
6/2020 FY-1.10--
Next Report Date23rd Sep 2019
Estimated EPS Next Report-0.30
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume313 373
Shares Outstanding (in ths.)2 654
Trades Count262
Dollar Volume185 629
Avg. Volume329 933
Avg. Weekly Volume793 661
Avg. Monthly Volume1 658 655
Avg. Quarterly Volume769 591
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
0 (0.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
RatingStrong Buy
1.00
Strong Buy
1.00
-

DelMar Pharmaceuticals Inc.

DelMar Pharmaceuticals Inc is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. The company's principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. DelMar also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. All the business activity of the firm is functioned through the region of Canada.

CEO: Saiid Zarrabian

Teplephone: +1 604 629-5989

Address: 999 West Broadway, Vancouver V5Z 1K5, BC, CAN

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

80%20%

Bearish Bullish

51%49%

Bearish Bullish

69%31%

News